Fig. 1

FKBP9 is elevated in high grade gliomas and correlates with poor prognosis. a Kaplan–Meier survival analysis of glioma samples from CGGA (n = 702), REMBRENDT (n = 619) and TCGA (n = 476) data, respectively (all p < 0.001). b Comparison of FKBP9 mRNA expression between low-grade gliomas (LGGs) and high-grade gliomas (HGGs) from the three databases used in (a). c Immunohistochemistry (IHC) analysis of FKBP9 on 40 specimens including low and high grade gliomas. Scale bar = 100 μm. Score according to the degree of cell staining and the proportion of positive cells. The protein expression level was shown as the product value of two scores (**p < 0.01). d Immunoblotting (IB) analysis for FKBP9 protein levels in GBM cell lines. α-Tubulin was used as a loading control. e Images for spheres of LN229, SF-539 and U-87 MG cells within 10 days of three dimensional (3D) culture. Scale bar = 200 μm (× 10). IB analysis for FKBP9, Sox2, Oct4 and Nanog protein levels in 2D and 3D cultured cells. α-Tubulin was used as a loading control. The ratios of FKBP9, Sox2 and Oct4 expression to their corresponding α-Tubulin were represented. f LN229, SF-539, T98G and U-87 MG cells were fixed for immunofluorescence (IF) and stained for FKBP9 (green), Calnexin (red) and DAPI (blue). Representative merged images were also shown for fluorescence signals. Scale bar = 25 μm. All experiments in this figure were performed three times with comparable results